Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 2
2013 1
2014 3
2015 3
2016 2
2017 3
2018 2
2019 4
2020 3
2021 6
2022 2
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
Immunogenicity and safety of varying dosages of a fifth-wave influenza A/H7N9 inactivated vaccine given with and without AS03 adjuvant in healthy adults.
Jackson LA, Stapleton JT, Walter EB, Chen WH, Rouphael NG, Anderson EJ, Neuzil KM, Winokur PL, Smith MJ, Schmader KE, Swamy GK, Thompson AB, Mulligan MJ, Rostad CA, Cross K, Tsong R, Wegel A, Roberts PC. Jackson LA, et al. Vaccine. 2024 Jan 12;42(2):295-309. doi: 10.1016/j.vaccine.2023.12.001. Epub 2023 Dec 16. Vaccine. 2024. PMID: 38105137 Free article. Clinical Trial.
Population pharmacokinetics and target attainment analyses to identify a rational empirical dosing strategy for cefepime in critically ill patients.
An G, Creech CB, Wu N, Nation RL, Gu K, Nalbant D, Jimenez-Truque N, Fissell W, Patel PC, Fishbane N, Watanabe A, Rolsma S, Kirkpatrick CMJ, Landersdorfer CB, Winokur P. An G, et al. J Antimicrob Chemother. 2023 Jun 1;78(6):1460-1470. doi: 10.1093/jac/dkad106. J Antimicrob Chemother. 2023. PMID: 37071586 Free PMC article.
Evaluation of Empirical Dosing Regimens for Meropenem in Intensive Care Unit Patients Using Population Pharmacokinetic Modeling and Target Attainment Analysis.
An G, Creech CB, Wu N, Nation RL, Gu K, Nalbant D, Jimenez-Truque N, Fissell W, Rolsma S, Patel PC, Watanabe A, Fishbane N, Kirkpatrick CMJ, Landersdorfer CB, Winokur P. An G, et al. Antimicrob Agents Chemother. 2023 Jan 24;67(1):e0131222. doi: 10.1128/aac.01312-22. Epub 2023 Jan 9. Antimicrob Agents Chemother. 2023. PMID: 36622154 Free PMC article.
Human Antibody Responses Following Vaccinia Immunization Using Protein Microarrays and Correlation With Cell-Mediated Immunity and Antibody-Dependent Cellular Cytotoxicity Responses.
Frey SE, Stapleton JT, Ballas ZK, Rasmussen WL, Kaufman TM, Blevins TP, Jensen TL, Davies DH, Tary-Lehmann M, Chaplin P, Hill H, Goll JB; DMID 09-0002 MVA Vaccine Study Group. Frey SE, et al. J Infect Dis. 2021 Oct 28;224(8):1372-1382. doi: 10.1093/infdis/jiab111. J Infect Dis. 2021. PMID: 33675226 Free PMC article. Clinical Trial.
Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older.
Winokur P, El Sahly HM, Mulligan MJ, Frey SE, Rupp R, Anderson EJ, Edwards KM, Bernstein DI, Schmader K, Jackson LA, Chen WH, Hill H, Bellamy A; DMID 13-0034 H7N9 Vaccine Study Group. Winokur P, et al. Vaccine. 2021 Feb 22;39(8):1339-1348. doi: 10.1016/j.vaccine.2020.11.051. Epub 2021 Jan 21. Vaccine. 2021. PMID: 33485646 Free PMC article. Clinical Trial.
Pharmacokinetics, Safety, and Tolerability of Oxfendazole in Healthy Adults in an Open-Label Phase 1 Multiple Ascending Dose and Food Effect Study.
Bach T, Galbiati S, Kennedy JK, Deye G, Nomicos EYH, Codd EE, Garcia HH, Horton J, Gilman RH, Gonzalez AE, Winokur P, An G. Bach T, et al. Antimicrob Agents Chemother. 2020 Oct 20;64(11):e01018-20. doi: 10.1128/AAC.01018-20. Print 2020 Oct 20. Antimicrob Agents Chemother. 2020. PMID: 32816721 Free PMC article. Clinical Trial.
31 results